

Innovotech Inc.
Suite L131, 2011 – 94 Street
Edmonton, Alberta
T6N 1H1

NEWS RELEASE

Innovotech Reports Notice of Allowance of a US Patent for Antimicrobial Silver Iodates in Gels

Edmonton, July 26, 2019. Innovotech Inc. (IOT, TSX-V), is pleased to report that it has received Notice of Allowance of a US patent (14/415,666) for its silver compounds, including InnovoSIL™-1 and AgreGuard™-1, which have broad activity against pathogens causing both bacterial and fungal infections.

Biofilms are organized communities of microorganisms that are notoriously difficult to eradicate. The Innovotech silver compounds have been shown to be very effective on biofilms associated with human, animal or plant infections.

InnovoSIL™-1 and AgreGuard™-1 have unusual stability in certain gels and are able to demonstrate a slow release, offering sustained antimicrobial activity. They have multiple mechanisms of action, and so it is more difficult for resistance to develop.

These compounds, in combination with gels, can bring valuable antimicrobial properties as coatings of surfaces or various medical, surgical, and wound devices; or could be used for direct application to infected skin, leaves or seeds.

Innovotech is actively seeking established industry partners interested in enhancing their products through the use of these outstanding products.

Dr. James Timourian
President
INNOVOTECH INC.
780.448.0585

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.